• Lexaria entered submissions seeking ethics clearance for Human Pilot Study #7, a five-week trial comparing two oral DehydraTECH-semaglutide formulations with Novo Nordisk’s oral Wegovy tablets.
• Results have not been presented; dosing is targeted to start in mid-June once quality-control testing and packaging are completed, with pre-dosing tasks expected to wrap by early June.
• Trial aims to assess safety, tolerability, and drug exposure over multiple weeks, focusing on whether DehydraTECH formulations can match or outperform commercial oral semaglutide while maintaining favorable tolerability.
• Study introduces a DehydraTECH semaglutide tablet format for first time, alongside a capsule, both using SNAC to support absorption in a longer-duration dosing regimen.
• Readout is positioned as a potential catalyst for commercial partnering interest tied to Lexaria’s oral drug delivery platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202605050910TNWSWRCACNPR_____1kx7FyZGb) on May 05, 2026, and is solely responsible for the information contained therein.